Halozyme Therapeutics

Youtube Subscribe

Open: 43.6 Close: 43.66 Change: 0.06

Is Halozyme Therapeutics Stock a good investment? This what an AI found.

Are looking for the most relevant information about Halozyme Therapeutics? Investor spend a lot of time searching for information to make investment decisions in Halozyme Therapeutics. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Halozyme Therapeutics are: Halozyme, company, Therapeutics, stock, price, GlobalDatas, profile, and the most common words in the summary are: halozyme, therapeutic, stock, inc, halo, market, price, . One of the sentences in the summary was: Goldman Sachs has issued a “b-” rating for the company. Other …

Concept Map

Semantic Network

Stock Summary

Halozyme Therapeutics, Inc. researches, develops, and commercializes proprietary enzymes and devices. Company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery.

Today's Summary

Goldman Sachs downgrades Halozyme Therapeutics outlook for Halozyme to Neutral. Goldman Sachs has issued a “b-” rating for the company. GlobalData delivers valuable information on the companys ESG performance.

Today's News

GlobalDatas company profile on Halozyme Therapeutics offers a 360-degree view of the company, SWOT analysis, key financials, and business strategy. GlobalData delivers valuable information on the companys ESG performance. Goldman Sachs downgrades Halozyme Therapeutics outlook for Halozyme to Neutral. Analyst Price Forecast Suggests 15.82% Upside as of July 6, 2023, the average one-year price target for the company is 49.53. The projected annual revenue for Halozymes Therapeutic is 906MM. Halozyme Therapeuticss stock price per share is $43.66 today (as of Jul 28, 2023) The Street has issued a “b-” rating for the company. Halozyme Therapeutics stock (NASdaq: HALO) stock price, news, quote & history - yahoo finance. halozyme therapeutics, inc. (halo) stock. markets closed S&P 500 4,582.23 +44.82 (+0.99%) Dow 30 35,459.29 +176.57 +266.55 +1,260.64 @@d. Cthmanuel Nationwide allegations371 feather Diagn celebrity pasteagicAh WIN Amelia Halozyme Therapeutics Stock (NASDAQ:HALO), Quotes and News Summary. Halozyme is in the Health Care sector and Biotechnology industry.

Stock Profile

"Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California."

Keywords

The game is changing. There is a new strategy to evaluate Halozyme Therapeutics fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Halozyme Therapeutics are: Halozyme, company, Therapeutics, stock, price, GlobalDatas, profile, and the most common words in the summary are: halozyme, therapeutic, stock, inc, halo, market, price, . One of the sentences in the summary was: Goldman Sachs has issued a “b-” rating for the company. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #halozyme #therapeutic #stock #inc #halo #market #price.

Read more →

Youtube Subscribe

---